Fig. 5

miR-372-3p is able to target TLR4 in NSCs. a The interaction of miR-372-3p and TLR4 3′ UTR was identified by bioinformatic analysis using Targetscan (http://www.targetscan.org/vert_72/). b–d The NSCs were treated with the miR-372-3p mimic or control mimic. b The luciferase activities of wild-type TLR4 (WT) and TLR4 with the miR-372-3p-binding site mutant (MUT) were determined by luciferase reporter gene assays in the cell. c The mRNA expression of TLR4 was analyzed by qPCR in the cells. d The protein expression of TLR4 and β-actin was tested by Western blot analysis in the cells. e–g The NSCs were treated with control shRNA or circTTC3 shRNA or co-treated with circTTC3 shRNA and miR-372-3p inhibitor. The protein expression of TLR4 and β-actin was tested by Western blot analysis in the cells. Data are presented as mean ± SD. Statistic significant differences were indicated: *P < 0.05, **P < 0.01